Litoximonostise reduces disease loss in RRMS patients
-
Last Update: 2020-07-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently announced the results of the 59th annual meeting of the American Association of Neurologists (ANN) in Boston, Usa in the United States: rituximab treatment of recurrent-relief multiple sclerosis (RRMS) can reduce the number of brain lesions in patientsRituximab is a therapeutic antibody that targets selective rejection of CD20-positive B cellsIn this phase II double-blind, placebo-controlled study, the researchers used magnetic resonance imaging brain scans to determine the total number of disease sepsis at 12, 16, 20 and 24 weeksThe results showed a statistically significant reduction in the number of lesions in the rituximatosis group at each point in time compared to the placebo group (p 0.0001)At the 24th week, the average cumulative total number of lesions per patient decreased by 91%, the rituxisis group was 0.5 and the placebo group was 5.5(white ice)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
